Latest stories on TEVA
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Business Insider64 · neutralm&a
Teva price target raised to $47 from $42 at Barclays
The Fly63 · neutralanalyst
Teva to Host R&D Day on Wednesday, November 11 in New York City
Business Insider52 · neutralproduct/pr
TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament
Barchart74 · bullishproduct/pr
JPMorgan raises Teva stock price target to $50 on Weltruza approval
Investing.com Analyst Ratings67 · bullishanalyst
Teva price target raised to $50 from $40 at JPMorgan
The Fly64 · neutralanalyst
Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy
Seeking Alpha53 · neutralanalyst
TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot
Stocktwits News84 · bullishproduct/pr
Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more
CNBC50 · neutralgeneral
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
Seeking Alpha74 · bullishproduct/pr
Oppenheimer raises Teva stock price target on Weltruza approval
Investing.com Analyst Ratings67 · bullishanalyst
Teva gains approval of monthly olanzapine injection for schizophrenia
Seeking Alpha74 · bullishproduct/pr
Teva Pharmaceuticals Shares Rise After FDA Approves Weltruza for Schizophrenia
MarketWatch74 · bullishproduct/pr
Teva wins FDA approval for monthly schizophrenia injection Weltruza
CNBC78 · bullishproduct/pr
Why is Teva Pharma stock surging today?
Investing.com Markets64 · neutralgeneral
Teva climbs premarket as FDA approves once-monthly schizophrenia treatment
Investing.com Markets74 · bullishproduct/pr
Teva Wins FDA Approval for WELTRUZA, a Once-Monthly Subcutaneous Olanzapine That Requires No Post-Injection Monitoring
MarketChameleon78 · bullishproduct/pr
Teva announces FDA approval for Weltruza
The Fly74 · bullishproduct/pr
Teva call volume above normal and directionally bullish
The Fly63 · neutralgeneral
Teva announces new data for ecopipam
The Fly59 · neutralproduct/pr
Teva announces published review on dopamine pathways in Tourette syndrome
The Fly59 · neutralproduct/pr
Teva, Samsung Bioepis expand strategic partnership to advance biosimilars
The Fly63 · neutralproduct/pr
Teva and Samsung Bioepis partner on up to six biosimilars
Seeking Alpha66 · bullishproduct/pr
Teva names Serge Rogasik as CEO of API, CDMO business
Seeking Alpha55 · neutralgeneral